Copy to clipboard 
SINTX Technologies executed a private label agreement to supply OsseoSculpt, a next-generation biologic designed to complement the company’s FDA 510(K)-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. SINTX recorded its first commercial revenue from OsseoSculpt in Q3 2025.
OsseoSculpt features a nanocrystalline HCA surface with a biomimetic pore architecture that provides an enhanced osteoconductive scaffold. SINTX will market this biologic alongside its SINAPTIC wedge system to augment bone healing in indicated procedures, providing surgeons with a streamlined solution from a single supplier.
The SINAPTIC wedge system, manufactured with silicon nitride biomaterial, is engineered to deliver stable correction in foot and ankle osteotomy procedures.
Commercial plan & near-term milestones:
- Limited release now through select design and early-adopter sites.
- Broader U.S. rollout aligned with wedge availability and surgeon training cycles through Q4 2025–Q1 2026.
- Growth drivers include targeted in-service education, case support, and data capture on attach rate, procedure time, and outcomes for evidence-driven adoption.
“Pairing our SINAPTIC wedges with a custom-built biologic closes a critical gap at the point of care,” said Lisa Marie Del Re, Chief Commercial Officer. “Design-surgeon feedback has been positive, and we recorded Q3 revenue from early evaluations. We expect biologic product utilization will improve the overall economic profile of our wedge portfolio as we scale commercialization.”
Source: SINTX Technologies, Inc.
